Blog From Niche to Necessity: Precision Medicine Isn’t an Initiative. It’s the New Infrastructure.By James Lu, MD, PhD, CEO and Co-Founder of Helix
Press ReleasesHelix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer CareAugust 7, 2025
Press ReleasesHelix Expands Pharmacogenomic Test Portfolio to Support Safer Cancer and Alzheimer’s TreatmentsMay 28, 2025
Press ReleasesHelix Launches 23,000-Patient Clinico-Genomic Cohort for Autoimmune Diseases to Advance Drug Discovery and DevelopmentMarch 18, 2025
VideosPartner Perspectives with Nebraska MedicineGenetic Insights Project helps Nebraskans take charge of their health
1Published ResearchFrom Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World EvidenceAugust 15, 2025
2Published ResearchNovel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse CohortJuly 30, 2025
3Published ResearchChatbot for the Return of Positive Genetic Screening Results for Hereditary Cancer Syndromes: Prompt Engineering ProjectJune 10, 2025
4Published ResearchIndividuals with PMS2 pathogenic variants are at average risk of cancer before age 60March 19, 2025
5Published ResearchScalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptionsMarch 19, 2025
Blog From Niche to Necessity: Precision Medicine Isn’t an Initiative. It’s the New Infrastructure.By James Lu, MD, PhD, CEO and Co-Founder of Helix
Press ReleasesHelix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer CareAugust 7, 2025
Press ReleasesHelix Expands Pharmacogenomic Test Portfolio to Support Safer Cancer and Alzheimer’s TreatmentsMay 28, 2025
Press ReleasesHelix Launches 23,000-Patient Clinico-Genomic Cohort for Autoimmune Diseases to Advance Drug Discovery and DevelopmentMarch 18, 2025
VideosPartner Perspectives with Nebraska MedicineGenetic Insights Project helps Nebraskans take charge of their health
1Published ResearchFrom Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World EvidenceAugust 15, 2025
2Published ResearchNovel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse CohortJuly 30, 2025
3Published ResearchChatbot for the Return of Positive Genetic Screening Results for Hereditary Cancer Syndromes: Prompt Engineering ProjectJune 10, 2025
4Published ResearchIndividuals with PMS2 pathogenic variants are at average risk of cancer before age 60March 19, 2025
5Published ResearchScalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptionsMarch 19, 2025
Blog Mar 19, 2024Unraveling the Power of Germline Clinico-Genomic Data: A Game Changer in Pharma's Drug Development Lifecycle
Press ReleasesMar 19, 2024Helix appoints Genentech and Flatiron Health Vet Hylton Kalvaria as SVP of Life Sciences
NewsMar 6, 2024Memorial Hermann Launches No-Cost Genetic Testing Program in HoustonPrecision Medicine Online
NewsMar 5, 2024Discover how Memorial Hermann’s new DNA screening program hopes to improve Houston’s health